The targeted cancer therapies market size is estimated to be USD 69,570 million in 2022 and is expected to witness a CAGR of 5.48% during the forecast period 2023-2033. The rising rates of malignancies, including gastrointestinal, colorectal, lung, and breast cancer, among others, expanding patient aid initiatives (PAPs), expanding government programs to raise awareness of cancer, increasing global cancer prevalence, and substantial R&D efforts from important players are factors contributing to the market growth. However, greater prices for these treatments and genetic diagnostic tests that identify cancer is expected to hinder the growth.

Segmentation

By Disease Indication

Based on disease indication, the market is segregated into gastrointestinal, lung cancer, breast, cancer, colorectal cancer, leukemia, lymphoma, melanoma, prostate cancer, and others. In 2022, the breast cancer segment held the highest market share owing to the strong trend of continual R&D among leading market companies involved in breast cancer therapies will result in the release of game-changing medicines in the future years and increasing demand for precise and effective treatment outcomes for the patient remains unmatched as more and more people across the world are receiving breast cancer diagnoses.

By End User

On the basis of end user, the market is categorized into hospitals, cancer and radiation therapy centers, and clinics. In 2022, the cancer and radiation therapy centers segment held the highest market share due to increasing the number of patients who choose less invasive outpatient operations that can be done in the doctor’s office rather than inpatient procedures that could need anaesthesia.

By Therapy Type

Based on therapy type, the market is divided into hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, and monoclonal antibodies. In 2022, the monoclonal antibodies segment held the highest market share owing to its benefits that it fights cancer by a number of techniques, including activating host immune functions to attack the target cell, attaching to ligands or receptors, and disrupting key cancer cell activities, and transporting a fatal payload to the target cell, such as a radioisotope or toxin.

Regional Markets

In 2022, North America region accounted for the highest revenue in the targeted cancer therapies market and is expected to maintain its dominance during the forecast period. This is attributed to the increased activity in mergers and acquisitions, rising technological advancements, increasing health insurance coverage, a rise in foreign direct investment, increasing elderly population, drastically altering lives, increased competition, and more widespread cancer insurance coverage. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to the rising consciousness, increasing cancer cases, and increasing government investment and demand.

Competitor Insights

Some of the key players operating in the targeted cancer therapies market are Sanofi (France), Pfizer, Inc (US). OncoGenex Pharmaceuticals Inc. (US), GlaxoSmithKline plc (UK), CYTOKINETICS INC. (US), Boehringer Ingelheim GmbH (Germany), Bayer AG (Germany), AVEO Pharmaceuticals Inc. (US), AstraZeneca PLC (UK), and Abbott Laboratories (US).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease indication, end user, and therapy type from 2023 to 2033.

Report Scope:

Segmentation: Targeted Cancer Therapies Market Report 2022 – 2033

Disease Indication (Revenue, USD Million), 2022 – 2033

• Gastrointestinal
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lymphoma
• Melanoma
• Prostate Cancer
• Others

End User (Revenue, USD Million), 2022 – 2033

• Hospitals
• Cancer and Radiation Therapy Centers
• Clinics

Therapy Type (Revenue, USD Million), 2022 – 2033

• Hormone Therapies
• Signal Transduction Inhibitors
• Gene Expression Modulators
• Apoptosis Inducers
• Angiogenesis Inhibitors
• Immunotherapies
• Monoclonal Antibodies

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA